<DOC>
	<DOCNO>NCT02965677</DOCNO>
	<brief_summary>To evaluate safety efficacy paclitaxel elute balloon dilatation catheter ( LEGFLOW OTW ) compare standard balloon ( Admiral Xtreme ) treatment stenosis occlusion femoral popliteal artery .</brief_summary>
	<brief_title>The Femoral Popliteal Artery Trial LEGFLOW OTW</brief_title>
	<detailed_description>To evaluate safety efficacy paclitaxel elute balloon dilatation catheter ( LEGFLOW OTW ) compare standard balloon ( Admiral Xtreme ) treatment stenosis occlusion femoral popliteal artery . This prospective , multicenter , prior desiged , randomize control study , plan enrol 172 subject . subject allocate 1:1 LEGFLOW OTW group n=86 Admiral Xtreme group n=86 . accept treatment LEGFLOW Admiral Xtreme balloon . follow day 0-30 , month 6 , 12 DUS clinical examination . endpoint data assess DUS core-lab , CEC , statisticed .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Age ≥ 18 year ≤ 85 year . 2 . De novo restenotic lesion femoral popliteal artery due atherosclerosis , locate superficial femoral artery and/or proximal popliteal artery ( arterial segment start least 1cm beyond common femoral artery bifurcation distal P1 segment popliteal artery level proximal edge patella ) . And patient suitable endovascular therapy LEGFLOW OTW Admiral Xtreme . 3 . Rutherford class 2 5 . 4 . Target lesion length ≤ 200mm . 5 . Target lesion stenosis ≥ 70 % total occlusion , pass common manipulation . 6 . Reference vessel diameter ≥ 4mm ≤ 8mm visual estimate . 7 . Target lesion consist single de novo restenotic lesion , adjacent lesion combination lesion multiple lesion meet follow criterion : adjacent lesion : ( 1 ) lesion space ≤ 30mm ; ( 2 ) total lesion length ( include lesion space ) ≤ 200mm ; ( 3 ) treat single lesion . Combination lesion : combination lesion define chronic total occlusion ( CTO ) , may include part total occlusion ( 100 % stenosis ) . The total lesion length ≤ 200mm . Multiple lesion : ( 1 ) lesion space &gt; 30mm ; ( 2 ) total lesion length ( include lesion space ) ≤ 200mm ; ( 3 ) treat multiple lesion . 8 . Angiographic evidence adequate distal runoff foot ( least one native calf vessel patent , define &lt; 50 % diameter stenosis ) , whether outfolw reestablish previous intervention . 9 . If subject ipsilateral/contralateral iliac disease require treatment procedure , iliac lesion must meet following criterion : Iliac lesion occlusion ≤ 100mm length ; must treat target lesion ( superficial femoral artery/proximal popliteal artery ) . must successfully treat target lesion treatment ; success define : ( 1 ) residual stenosis &lt; 30 % ; ( 2 ) free dissection limit blood flow ; ( 3 ) occurrence thrombus , embolization , SAE . 10 . Life expectancy one year . 11 . Understands study objective willing participate provide inform consent form , willing comply specify followup evaluation specify time point . 1 . Women childbearing age negative pregnancy test procedure , breastfeed woman . 2 . Stroke STEMI within 30 day prior procedure . 3 . Either local systemic thrombolytic therapy within 6 week prior procedure . 4 . Any major surgical operation ( operation class ≥ 3 ) interventional therapy within 30 day prior procedure . 5 . Any major selective surgical operation ( operation class ≥ 3 ) interventional therapy within 30 day prior procedure . 6 . Restenotic lesion DCB bypass surgery . 7 . Target limb previously treat bypass surgery . 8 . Guidewire must pass distal part limb . 9 . Known allergy sensitivity contrast agent , paclitaxel , antiplatelet , anticoagulant thrombolytic drug . 10 . Known allergy sensitivity heparin , include patient previous incidence heparininduced thrombocytopenia ( HIT ) type II . 11 . Aneurysm locate target vessel . 12 . Acute subacute thrombosis target vessel . 13 . Angiographic evidence severe calcification ( define dense circumferential calcification make target lesion nondilatable and/or calcificatin present side vessel wall extend 5 cntinuous centimeter length within target lesion prior contrast injection digital subtraction angiography ) . 14 . The bilateral low limb must treat one procedure . 15 . Uncorrected bleed disorder . 16 . Renal insufficiency ( serum creatinine &gt; 2.5mg/dL renal dialysis ) . 17 . Stenosis occlusion due nonatherosclerosis , thrombotic occlusive vasculitis vasculitis . 18 . Septicemia bacteremia . 19 . Patients severe disease ( severe chronic obstructive pulmonary disease , malignant tumor , dementia , etc . ) patient 's physical condition may affect compliance study . 20 . Predilation result major ( ≥ Grade D ) flowlimiting dissection residual stenosis &gt; 70 % . 21 . Major distal amputation ( transmetatarsal ) study limb nonstudy limb . 22 . Patients participate another investigational drug device trial complete primary endpoint .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>drug elute balloon</keyword>
	<keyword>Femoral Popliteal Artery</keyword>
</DOC>